Erythropoietin receptor binding antibodies
AssigneeAbbott Laboratories
InventorsPeter J. DeVries, David H. Ostrow, Edward B. Reilly, Larry L. Green, James Wieler
Life of this patent
Estimating the term…
Abstract
The present invention relates to antibodies and antibody fragments thereof that bind to and activate an erythropoietin receptor. The present invention also relates to methods of modulating the endogenous activity of an erythropoietin receptor in a mammal using said antibodies as well as pharmaceutical compositions containing said antibodies.
Claims60
An antibody or antibody fragment thereof that activates an endogenous activity of a human erythropoietin receptor in a mammal but does not interact with a peptide having an amino acid sequence of SEQ ID NO:1.
An antibody or antibody fragment thereof that is capable of activating an endogenous activity of a human erythropoietin receptor in a mammal, wherein said antibody or antibody fragment thereof exhibits a binding affinity within one hundred fold of the binding affinity of endogenous human erythropoietin to the erythropoietin receptor.
An antibody or antibody fragment thereof that activates an endogenous activity of a human erythropoietin receptor in a mammal, comprising at least one heavy chain variable region having the amino acid sequence of SEQ ID NO:
- 3 or antibody fragment thereof;
- wherein said antibody or antibody fragment thereof does not interact with a peptide having an amino acid sequence of SEQ ID NO:1.
An antibody or antibody fragment thereof that activates an endogenous activity of a human erythropoietin receptor in a mammal, comprising at least one light chain variable region having the amino acid sequence of SEQ ID NO:
- 5 or antibody fragment thereof;
- wherein said antibody or antibody fragment thereof does not interact with a peptide having an amino acid sequence of SEQ ID NO:1.
An antibody or antibody fragment thereof that activates an endogenous activity of a human erythropoietin receptor in a mammal, comprising:
- at least one heavy chain variable region having the amino acid sequence of SEQ ID NO:
- 3 or antibody fragment thereof;
- and
- at least one light chain variable region having the amino acid sequence of SEQ ID NO:
- 5 or antibody fragment thereof,
- wherein said antibody or antibody fragment thereof does not interact with a peptide having an amino acid sequence of SEQ ID NO:1.
An antibody or antibody fragment thereof that activates an endogenous activity of a human erythropoietin receptor in a mammal, comprising
- at least one heavy chain variable region having the amino acid sequence of SEQ ID NO:
- 7 or antibody fragment thereof;
- wherein said antibody or antibody fragment thereof does not interact with a peptide having an amino acid sequence of SEQ ID NO:1.
An antibody or antibody fragment thereof that activates an endogenous activity of a human erythropoietin receptor in a mammal, comprising
- at least one light chain variable region having the amino acid sequence of SEQ ID NO:
- 9 or antibody fragment thereof;
- wherein said antibody or antibody fragment thereof does not interact with a peptide having an amino acid sequence of SEQ ID NO:1.
An antibody or antibody fragment thereof that activates an endogenous activity of a human erythropoietin receptor in a mammal, said antibody comprising:
- at least one heavy chain variable region having the amino acid sequence of SEQ ID NO:
- 7 or antibody fragment thereof;
- and
- at least one light chain variable region having the amino acid sequence of SEQ ID NO:
- 9 or antibody fragment thereof,
- wherein said antibody or antibody fragment thereof does not interact with a peptide having an amino acid sequence of SEQ ID NO:1.
An antibody or antibody fragment thereof that activates an endogenous activity of a human erythropoietin receptor in a mammal, comprising
- at least one heavy chain variable region having the amino acid sequence selected from the group consisting of SEQ ID NO:
- 11, 15, 19, 31, 35, 39,43, 47, 51 and 55 or antibody fragment thereof, wherein said antibody or antibody fragment thereof does not interact with a peptide having an amino acid sequence of SEQ ID NO:1.
An antibody or antibody fragment thereof that activates an endogenous activity of a human erythropoietin receptor in a mammal, comprising
- at least one light chain variable region having the amino acid sequence of SEQ ID NO:
- 13, 17, 21, 23, 25, 27, 29, 33, 37, 41, 45, 49, 53 and 57 or antibody fragment thereof, wherein said antibody or antibody fragment thereof does not interact with a peptide having an amino acid sequence of SEQ ID NO:1.
An antibody or antibody fragment thereof that activates an endogenous activity of a human erythropoietin receptor in a mammal, said antibody comprising:
- the amino acid sequences of at least one heavy chain variable region and at least one light chain variable region selected from the group consisting of SEQ ID NO:11/SEQ ID NO:13, SEQ ID NO:15/SEQ ID NO:17, SEQ ID NO:19/SEQ ID NO:21, SEQ ID NO:11/SEQ ID NO:23, SEQ ID NO:11/SEQ ID NO:25, SEQ ID NO:11/SEQ ID NO:27, SEQ ID NO:11/SEQ ID NO:29, SEQ ID NO:31/SEQ ID NO:33, SEQ ID NO:35/SEQ ID NO:37, SEQ ID NO:39/SEQ ID NO:41, SEQ ID NO:43/SEQ ID NO:45, SEQ ID NO:47/SEQ ID NO:49, SEQ ID NO:51/SEQ ID NO:53 and SEQ ID NO:55/SEQ ID NO:57 or antibody fragment thereof, wherein said antibody or antibody fragment thereof does not interact with a peptide having an amino acid sequence of SEQ ID NO:1.
An isolated antibody or antibody fragment thereof capable of binding to a human erythropoietin receptor in a mammal, said antibody comprising:
- at least one heavy chain variable region having the amino acid sequence of SEQ ID NO:
- 3 or antibody fragment thereof.
An isolated antibody or antibody fragment thereof capable of binding to a human erythropoietin receptor in a mammal, said antibody comprising:
- at least one light chain variable region having the amino acid sequence of SEQ ID NO:
- 5 or antibody fragment thereof.
An isolated antibody or antibody fragment thereof capable of binding to a human erythropoietin receptor in a mammal, said antibody comprising:
- at least one heavy chain variable region having the amino acid sequence of SEQ ID NO:
- 7 or antibody fragment thereof.
An isolated antibody or antibody fragment thereof capable of binding to a human erythropoietin receptor in a mammal, said antibody comprising:
- at least one light chain variable region having the amino acid sequence of SEQ ID NO:
- 9 or antibody fragment thereof.
An isolated antibody or antibody fragment thereof capable of binding to a human erythropoietin receptor in a mammal, said antibody comprising:
- at least one heavy chain variable region having the amino acid sequence of SEQ ID NO:
- 11 or antibody fragment thereof.
An isolated antibody or antibody fragment thereof capable of binding to a human erythropoietin receptor in a mammal, said antibody comprising:
- at least one light chain variable region having the amino acid sequence of SEQ ID NO:
- 13 or antibody fragment thereof.
An isolated antibody or antibody fragment thereof capable of binding to a human erythropoietin receptor in a mammal, said antibody comprising:
- at least one heavy chain variable region having the amino acid sequence of SEQ ID NO:
- 15 or antibody fragment thereof.
An isolated antibody or antibody fragment thereof capable of binding to a human erythropoietin receptor in a mammal, said antibody comprising:
- at least one light chain variable region having the amino acid sequence of SEQ ID NO:
- 17 or antibody fragment thereof.
An isolated antibody or antibody fragment thereof capable of binding to a human erythropoietin receptor in a mammal, said antibody comprising:
- at least one heavy chain variable region having the amino acid sequence of SEQ ID NO:
- 19 or antibody fragment thereof.
An isolated antibody or antibody fragment thereof capable of binding to a human erythropoietin receptor in a mammal, said antibody comprising:
- at least one light chain variable region having the amino acid sequence of SEQ ID NO:
- 21 or antibody fragment thereof.
An isolated antibody or antibody fragment thereof capable of binding to a human erythropoietin receptor in a mammal, said antibody comprising:
- at least one light chain variable region having the amino acid sequence of SEQ ID NO:
- 23 or antibody fragment thereof.
An isolated antibody or antibody fragment thereof capable of binding to a human erythropoietin receptor in a mammal, said antibody comprising:
- at least one light chain variable region having the amino acid sequence of SEQ ID NO:
- 25 or antibody fragment thereof.
An isolated antibody or antibody fragment thereof capable of binding to a human erythropoietin receptor in a mammal, said antibody comprising:
- at least one light chain variable region having the amino acid sequence of SEQ ID NO:27 or antibody fragment thereof.
An isolated antibody or antibody fragment thereof capable of binding to a human erythropoietin receptor in a mammal, said antibody comprising:
- at least one light chain variable region having the amino acid sequence of SEQ ID NO:29 or antibody fragment thereof.
An isolated antibody or antibody fragment thereof capable of binding to a human erythropoietin receptor in a mammal, said antibody comprising:
- at least one heavy chain variable region having the amino acid sequence of SEQ ID NO:31 or antibody fragment thereof.
An isolated antibody or antibody fragment thereof capable of binding to a human erythropoietin receptor in a mammal, said antibody comprising:
- at least one light chain variable region having the amino acid sequence of SEQ ID NO:33 or antibody fragment thereof.
An isolated antibody or antibody fragment thereof capable of binding to a human erythropoietin receptor in a mammal, said antibody comprising:
- at least one heavy chain variable region having the amino acid sequence of SEQ ID NO:35 or antibody fragment thereof.
An isolated antibody or antibody fragment thereof capable of binding to a human erythropoietin receptor in a mammal, said antibody comprising:
- at least one light chain variable region having the amino acid sequence of SEQ ID NO:
- 37 or antibody fragment thereof.
An isolated antibody or antibody fragment thereof capable of binding to a human erythropoietin receptor in a mammal, said antibody comprising:
- at least one heavy chain variable region having the amino acid sequence of SEQ ID NO:
- 39 or antibody fragment thereof.
An isolated antibody or antibody fragment thereof capable of binding to a human erythropoietin receptor in a mammal, said antibody comprising:
- at least one light chain variable region having the amino acid sequence of SEQ ID NO:41 or antibody fragment thereof.
An isolated antibody or antibody fragment thereof capable of binding to a human erythropoietin receptor in a mammal, said antibody comprising:
- at least one heavy chain variable region having the amino acid sequence of SEQ ID NO:
- 43 or antibody fragment thereof.
An isolated antibody or antibody fragment thereof capable of binding to a human erythropoietin receptor in a mammal, said antibody comprising:
- at least one light chain variable region having the amino acid sequence of SEQ ID NO:
- 45 or antibody fragment thereof.
An isolated antibody or antibody fragment thereof capable of binding to a human erythropoietin receptor in a mammal, said antibody comprising:
- at least one heavy chain variable region having the amino acid sequence of SEQ ID NO:
- 47 or antibody fragment thereof.
An isolated antibody or antibody fragment thereof capable of binding to a human erythropoietin receptor in a mammal, said antibody comprising:
- at least one light chain variable region having the amino acid sequence of SEQ ID NO:
- 49 or antibody fragment thereof.
An isolated antibody or antibody fragment thereof capable of binding to a human erythropoietin receptor in a mammal, said antibody comprising:
- at least one heavy chain variable region having the amino acid sequence of SEQ ID NO:
- 51 or antibody fragment thereof.
An isolated antibody or antibody fragment thereof capable of binding to a human erythropoietin receptor in a mammal, said antibody comprising:
- at least one light chain variable region having the amino acid sequence of SEQ ID NO:
- 53 or antibody fragment thereof.
An isolated antibody or antibody fragment thereof capable of binding to a human erythropoietin receptor in a mammal, said antibody comprising:
- at least one heavy chain variable region having the amino acid sequence of SEQ ID NO:
- 55 or antibody fragment thereof.
An isolated antibody or antibody fragment thereof capable of binding to a human erythropoietin receptor in a mammal, said antibody comprising:
- at least one light chain variable region having the amino acid sequence of SEQ ID NO:
- 57 or antibody fragment thereof.
An isolated antibody capable of binding a human erythropoietin receptor in a mammal, said antibody comprising a heavy chain variable region comprising a continuous sequence from CDR1 through CDR3 having the amino acid sequence selected from the group consisting of:
- SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, and SEQ ID NO:61 and fragments thereof.
An isolated antibody capable of binding a human erythropoietin receptor in a mammal, said antibody comprising a light chain variable region comprising a continuous sequence from CDR1 through CDR3 having the amino acid sequence selected from the group consisting of:
- SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:77, SEQ ID NO:78 and fragments thereof.
A method of activating an endogenous activity of a human erythropoietin receptor in a mammal, the method comprising the step of administering to said mammal a therapeutically effective amount of an antibody or antibody fragment thereof to activate said receptor, wherein said antibody or antibody fragment thereof does not interact with a peptide having an amino acid sequence of SEQ ID NO:1.
A method of treating a mammal suffering aplasia, the method comprising the step of administering to a mammal in need of treatment a therapeutically effective amount of an antibody or antibody fragment thereof to activate said receptor, wherein said antibody or antibody fragment thereof does not interact with a peptide having an amino acid sequence of SEQ ID NO:1.
A pharmaceutical composition comprising a therapeutically effective amount of an antibody or antibody fragment thereof and a pharmaceutically acceptable excipient, wherein said antibody or antibody fragment thereof does not interact with a peptide having an amino acid sequence of SEQ ID NO:1.
An isolated and purified polynucleotide sequence selected from the group consisting of:
- SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, fragments, complements, and degenerate codon equivalents thereof.
An isolated and purified amino acid sequence selected from the group consisting of:
- SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68 and fragments thereof.
An antibody or antibody fragment thereof that activates an endogenous activity of a human erythropoietin receptor in a mammal wherein said antibody or antibody fragment is a gamma-2 isotype.
Dependencies are inferred from the claim text.